In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, significant M&A activity, key regulatory approvals, and notable pipeline developments shaped the global pharma landscape. Meanwhile, pricing decisions and policy shifts continue to influence market dynamics and strategic positioning.
M&A and Strategic Deals
-
Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05B expands its footprint in the metabolic disease space.
Read more → -
Biogen’s partnership with Dayra aims to enhance its immunological disease portfolio, indicating a strategic focus on immune-mediated conditions.
Read more →
Regulatory and Approvals
-
Otsuka secured FDA approval for Voyxact in kidney disease, marking a significant step in addressing this unmet medical need.
Read more → -
Regeneron’s Eylea HD received FDA approvals, potentially strengthening its market position in the eye care segment.
Read more →
Pipeline and R&D Highlights
-
Kelun and Merck’s ADC shows promise in lung cancer treatment, potentially offering a new therapeutic option for patients.
Read more → -
Bayer’s Asundexian trial shows promise in stroke prevention, potentially adding a new weapon to the arsenal against this prevalent condition.
Read more →
Market, Pricing and Policy Signals
-
Novo Nordisk’s launch of Wegovy at $349 signals a competitive pricing strategy in the obesity market.
Read more → -
The CMS setting 2027 Medicare prices for Wegovy and Trelegy could have far-reaching implications for these drugs’ market access and uptake.
Read more →
Stay updated — follow PharmaSignal on LinkedIn and visit PharmaSignal.com for daily global pharma insights.